ArticleAmerican journal of translational research2019
A novel human-derived tissue-engineered patch for vascular reconstruction.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evolutions in Cardiovascular Implants-A Review of Past, Present, and Future.Micromachines · 2026Review
- Cardiac tissue engineering for the treatment of hypoplastic left heart syndrome (HLHS).Translational pediatrics · 2023Review
- Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches.Frontiers in bioengineering and biotechnology · 2022Article
- The Real Need for Regenerative Medicine in the Future of Congenital Heart Disease Treatment.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular patches are commonly applied in tissue repair and reconstruction in congenital cardiac surgery. However, the currently available patch materials are inappropriate to be used in the pediatric population due to their lack of supporting tissue growth potential. In our study an active patch material was developed by seeding pediatric patient's bone marrow stem cells on a decellularized aortic extracellular matrix (ECM) scaffold. The patch was then implanted to repair abdominal aorta defects of nude rats. Two months after implantation, tissue remodeling, vascular cell regeneration, and cellular integration were investigated using histology and fluorescent staining. Histology demonstrated infiltration of host cells and formation of organized cell layers as well as intact collagen and elastic fibers inside the patch material. Immunofluorescence indicated regeneration of endothelial and smooth muscle cells. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified multiple vascularization-promoting components and growth factors in decellularized aortic ECM scaffold. These results demonstrated growth potential and suitability of human derived tissue-engineered patch for vascular reconstruction, and thus, it might be considered in the future as treatment option in pediatric patients.
Indexed as
Identifiers
31217871PMC6556661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.